EUVIMEDEUVIMED entdecken
Crossref

Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells

Sebastien A Burel, Todd Machemer, Brenda F Baker, T Jesse Kwoh, Suzanne Paz iD, Husam Younis, Scott P Henry

Nucleic Acid Therapeutics · 01.12.2022 · 32 (6) · 457-472

DOI: 10.1089/nat.2022.0033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.12.2022. Verfasst von Sebastien A Burel und 6 weiteren Autor:innen. Beteiligte Einrichtung: IONIS Pharmaceuticals, Inc., Carlsbad, California, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Leukocytes, Mononuclear. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A human peripheral blood mononuclear cell (PBMC)-based assay was developed to identify antisense oligonucleotide (ASO) with the potential to activate a cellular innate immune response outside of an acceptable level. The development of this assay was initiated when ISIS 353512 targeting the messenger ribonucleic acid for human C-reactive protein (CRP) was tested in a phase I clinical trial, in which healthy human volunteers unexpectedly experienced increases in interleukin-6 (IL-6) and CRP. This level of immune stimulation was not anticipated following rodent and nonhuman primate safety studies in which no evidence of exaggerated proinflammatory effects were observed. The IL-6 increase induced by ISIS 353512 was caused by activation of B cells. The IL-6 induction was inhibited by chloroquine pretreatment of PBMCs and the nature of ASOs suggested that the response is mediated by a Toll-like receptor (TLR), in all likelihood TLR9. While assessing the inter PBMC donor variability, two classes of human PBMC responders to ISIS 353512 were identified (discriminator and nondiscriminators). The discriminator donor PBMCs were shown to produce low level of IL-6 after 24 h in culture, in the absence of ASO treatment. The PBMC assay using discriminator donors was shown to be reproducible, allowing to assess reliably the immune potential of ASOs by comparison to known benchmark ASO controls that were previously shown to be either safe or inflammatory in clinical trials. Clinical Trial registration numbers: NCT00048321 NCT00330330 NCT00519727.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseLeukocytes, MononuclearHumansHealthy VolunteersInterleukin-6

Stichwörter der Autor:innen

antisenseinflammatoryoligonucleotides

Substanzen

Oligonucleotides, AntisenseInterleukin-6

Autor:innen und Institutionen

  • IONIS Pharmaceuticals, Inc., Carlsbad, California, USA.

ORCID-Profile: Suzanne Paz

Zitieren

APA

Burel, S. A., Machemer, T., Baker, B. F., Kwoh, T. J., Paz, S., Younis, H., & Henry, S. P. (2022). Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. Nucleic Acid Therapeutics, 32(6), 457-472. https://doi.org/10.1089/nat.2022.0033

Vancouver

Burel SA, Machemer T, Baker BF, Kwoh TJ, Paz S, Younis H, et al. Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. Nucleic Acid Therapeutics. 2022;32(6):457-472. doi:10.1089/nat.2022.0033

BibTeX
@article{Burel2022,
  author = {Burel, Sebastien A and Machemer, Todd and Baker, Brenda F and Kwoh, T Jesse and Paz, Suzanne and Younis, Husam and Henry, Scott P},
  title = {Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells},
  journal = {Nucleic Acid Therapeutics},
  year = {2022},
  volume = {32},
  number = {6},
  pages = {457--472},
  doi = {10.1089/nat.2022.0033}
}
Kostenlos starten →